---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-089065"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:41.440353+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Quoin posts Q2 net loss of $2.0M; cash $12.6M; expands Netherton trials internationally

## Summary
- Cash, cash equivalents and marketable securities of $12.6M as of June 30, 2024; expected to fund operations into late 2025.
- Net loss for Q2 2024 was $2.0M ($2.1M in Q2 2023); six-month net loss $4.3M ($4.7M in prior year).
- Signed research agreement with University College Cork for topical rapamycin formulations using dissolvable microneedle technology.
- Expanded Netherton Syndrome clinical trials to international sites starting with Saudi Arabia and EU.
- Announced plans to initiate clinical study in Peeling Skin Syndrome, first site and patient identified.

## SEC filing metadata
- accession: 0001104659-24-089065
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465924089065/0001104659-24-089065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465924089065/tm2421595d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-089065
- JSON: https://secwatch.observer/filing/0001104659-24-089065.json
- Plain text: https://secwatch.observer/filing/0001104659-24-089065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.